Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Share-based Compensation (2016 - 2025)

Wave Life Sciences (WVE) has disclosed Share-based Compensation for 11 consecutive years, with $7.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 126.63% year-over-year to $7.4 million, compared with a TTM value of $25.0 million through Dec 2025, up 90.04%, and an annual FY2025 reading of $25.0 million, up 90.04% over the prior year.
  • Share-based Compensation was $7.4 million for Q4 2025 at Wave Life Sciences, up from $6.5 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $7.4 million in Q4 2025 and bottomed at $2.3 million in Q3 2023.
  • Average Share-based Compensation over 5 years is $4.1 million, with a median of $3.5 million recorded in 2024.
  • The sharpest move saw Share-based Compensation skyrocketed 155.33% in 2022, then tumbled 65.34% in 2023.
  • Year by year, Share-based Compensation stood at $3.7 million in 2021, then decreased by 21.98% to $2.9 million in 2022, then decreased by 19.09% to $2.4 million in 2023, then soared by 37.93% to $3.2 million in 2024, then soared by 126.63% to $7.4 million in 2025.
  • Business Quant data shows Share-based Compensation for WVE at $7.4 million in Q4 2025, $6.5 million in Q3 2025, and $6.2 million in Q2 2025.